Mazur Leonard L Insider Trades

Insider Trading History

Track insider trading activity for Mazur Leonard L. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Citius Oncology
Citius Oncology CTOR
Chief Executive Officer
Holding Value $1.35M 1,700,000 shares
Last Trade
Sep 19, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.99M 1,700,000 shares
$1.76
$0.80
Citius Pharmaceuticals
Citius Pharmaceuticals CTXR
Chief Executive Officer
Holding Value $74k 125,490 shares
Last Trade
Aug 08, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$264k 214,878 shares
$1.23
$0.59
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Aug 08, 2025 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$31k 214,878 shares
$0.14
$0.14
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
Chief Executive Officer
Holding Value $18.1k 125,490 shares
Last Trade
Aug 08, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$31k 214,878 shares
$0.14
$0.14
Citius Pharmaceuticals
Citius Pharmaceuticals CTXR
Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Aug 08, 2025 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$264k 214,878 shares
$1.23
$0.59
Citius Oncology
Citius Oncology CTOR
Chief Executive Officer
Holding Value $637k 800,000 shares
Last Trade
Dec 12, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$856k 800,000 shares
$1.07
$0.80
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
10% owner, Chief Executive Officer
Holding Value $86.5k 600,000 shares
Last Trade
Nov 07, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$86.5k 600,000 shares
$0.14
$0.14
Citius Pharmaceuticals
Citius Pharmaceuticals CTXR
10% owner, Chief Executive Officer
Holding Value $354k 600,000 shares
Last Trade
Nov 07, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.74M 600,000 shares
$9.56
$0.59
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
10% owner, Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Sep 25, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$322k 2,234,700 shares
$0.14
$0.14
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
10% owner, Chief Executive Officer
Holding Value $322k 2,234,700 shares
Last Trade
Sep 25, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$322k 2,234,700 shares
$0.14
$0.14
Citius Pharmaceuticals
Citius Pharmaceuticals CTXR
10% owner, Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Sep 25, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$28.8M 2,234,700 shares
$12.91
$0.59
Citius Pharmaceuticals
Citius Pharmaceuticals CTXR
10% owner, Chief Executive Officer
Holding Value $1.32M 2,234,700 shares
Last Trade
Sep 25, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$28.8M 2,234,700 shares
$12.91
$0.59
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
10% owner, Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Aug 14, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$452k 3,137,255 shares
$0.14
$0.14
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
10% owner, Chief Executive Officer
Holding Value $452k 3,137,255 shares
Last Trade
Aug 14, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$452k 3,137,255 shares
$0.14
$0.14
Citius Pharmaceuticals
Citius Pharmaceuticals CTXR
10% owner, Chief Executive Officer
Holding Value $1.85M 3,137,255 shares
Last Trade
Aug 14, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$46.3M 3,137,255 shares
$14.75
$0.59
Citius Pharmaceuticals
Citius Pharmaceuticals CTXR
10% owner, Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Aug 14, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$46.3M 3,137,255 shares
$14.75
$0.59
Citius Oncology
Citius Oncology CTOR
Chief Executive Officer
Holding Value $982k 1,233,333 shares
Last Trade
Aug 12, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$0.80
Citius Oncology
Citius Oncology CTOR
Chief Executive Officer
Holding Value $2.94M 3,700,000 shares
Last Trade
Aug 12, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$0.80
Tharimmune
Tharimmune THAR
Director
Holding Value $96.8k 27,353 shares
Last Trade
Aug 09, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$6.89k 2,353 shares
$2.93
$3.54
Citius Pharmaceuticals- Warrants(02/08/2022)
Citius Pharmaceuticals- Warrants(02/08/2022) CTXRW
10% owner, Chief Executive Officer
Holding Value $0 0 shares
Last Trade
Apr 03, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$168k 1,165,048 shares
$0.14
$0.14

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up